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The Pulmonary Center at Boston University School of Medicine, Boston, MA,  
USA 
1. Introduction 
The oxidant-antioxidant hypothesis and asthma: The pathogenesis of asthma is unknown 
but imbalances between oxidants and antioxidants are believed to play a fundamental role. 
One key component of the oxidant-antioxidant hypothesis centers on the huge burden of 
oxidants derived from inflammatory cell infiltration into the lung. The eosinophil, in 
particular, is implicated as a major source of oxidative injury, including protein nitration 1. 
Dysfunctional mitochondria in lung cells are another potential source of oxidants. 
Mitochondrial injury to airway epithelium occurs in murine models of allergic asthma 2, 3. 
There is evidence to support its role in human asthma as well including increased oxidative 
injury to mitochondrial epithelial cell superoxide dismutase (SOD) 4, enhanced 
mitochondrial proliferation in bronchial smooth muscle 5, and mutations in mitochondrial 
DNA 6. Overall, this oxidative burden, generated by both inflammatory and lung cells, can 
overwhelm antioxidant defense to cause oxidant stress during asthma. This stress can alter 
or inactivate the function of essential proteins, lipids and nucleic acids culminating in severe 
cell injury, dysfunction and death.  
An accumulating body of literature suggests that oxidant stress is an important factor in 
asthma pathogenesis 7-11. Oxidant stress can impact the function of a number of different cell 
types in the lung, and new research has drawn attention to immune cells and airway 
epithelial cells for the following reasons. First, immune cells are located within the lung and 
are directly exposed to inhaled allergens so that the local antioxidant milieu of the lung may 
impact the magnitude of oxidant stress in these cells. Second, antioxidant supplements, 
including glutathione precursors 12, 13 have been shown to alter the cellular redox milieu of 
immune cells and effect pro-inflammatory cytokine production and inflammatory load in 
the lung (Figure 1). Third, as described above, the airway epithelium appears to be one 
cellular target that is subject to mitochondrial injury in asthma and in murine asthma 
models. Fourth, studies from the author’s laboratory suggest that extracellular glutathione 
within the lung lining fluid has a robust impact on airway epithelial cell responses to 
inflammation and the development of airway hyperreactivity (AHR). AHR may be related 
to airway epithelial cell integrity and maintenance of barrier function 14. These data suggest 
that the source and the location of oxidative stress, as well as the nature of the oxidant(s) to 
be targeted, are likely to impact the success of an antioxidant intervention. Nonetheless, 
broader based interventions have also shown some success in animal models, as discussed 
below. 
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Fig. 1. Murine Models of Allergic Asthma. Two general models are driven by ovalbumin as 
allergen, or IL13 as pro-inflammatory cytokine. Cellular antioxidants, such as glutathione, 
can affect the redox milieu of immune cells to attenuate pro-inflammatory cytokine 
induction (12). Extracellular antioxidants, such as lung lining fluid (LLF) glutathione, can 
buffer reactive oxygen species (ROS) from inflammatory cells, protect airway epithelial cells 
against oxidant stress and prevent airway hyperreactivity (14). 
Oxidant stress, transcription factor NF-E2 related factor 2 (Nrf2) and asthma: Cellular 
antioxidants effectively buffer oxidants generated by metabolism or inhaled during 
ventilation in the normal lung. Oxidant stress results when the oxidant burden exceeds 
antioxidant defense and this elicits a cellular response to increase antioxidant capacity and 
restore balance. Recent studies have identified a central component of this endogenous 
antioxidant response pathway as transcription factor NF-E2 related factor 2, also known as 
Nrf2 15, 16. Nrf2 is a basic leucine zipper transcription factor and a member of the cap-n-collar 
family of transcription factors. It recognizes a core promoter DNA sequence known as the 
"antioxidant responsive element” (ARE) and up-regulates several antioxidant and phase 2 
detoxifying genes in cells. Targeted deletion of Nrf2 in mice produces no obvious phenotype 
under normal conditions 17. But Nrf2 null mice exhibit increased susceptibility to oxidant 
stress from pro-oxidant agents such as acetaminophen, which causes liver failure 18, and 
butylated hydroxytoluene, which causes respiratory failure 19. Nrf2 deficient mice are also 
sensitive to several oxidant-mediated injuries in the lung, including exposure to hyperoxia 20 
and bleomycin 21. A common theme in this susceptibility centers on uncompensated oxidant 
stress which causes excess inflammation along with extensive cell injury leading to cell 
death and organ failure. An expanding literature now supports Nrf2 as a general regulator 
of the ARE-mediated cellular antioxidant defense system that enables cell to survive under 
oxidant stress 15, 22. The biological relevance of the Nrf2 pathway continues to expand with 
recent descriptions of its interaction with the notch1 signaling pathway during tissue 
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regeneration 23 and the p53/p21 pathway during cell cycle control in response to oxidant-
mediated DNA damage 24. In fact, the known susceptibility of the p21 deficient lung to 
oxidant stress may result from lack of the p21 protein-protein interaction that liberates Nrf2 
from its cytoplasmic inhibitor Keap1 25. Previous studies have documented induction of p21 
protein in airway epithelial cells with asthma. This novel interaction with Nrf2 suggests a 
biological couple between cell cycle arrest and antioxidant activation that enables cell 
survival under oxidant stress 26.  
The relevance of Nrf2 to oxidant stress and asthma stems from the fact that Nrf2 null mice 
are more susceptible to asthma than normal mice using ovalbumin to model experimental 
allergic airway disease 11. Oxidant stress, inflammation, airway hyperreactivity and mucus 
induction are magnified in the lungs of Nrf2 null mice compared to normal mice 27. Oxidant 
stress was quantified by total lung glutathione which rose in the normal lung, largely as 
reduced glutathione (GSH), but not in the Nrf2 null lung. The genes for glutathione 
synthesis were identified as Nrf2-targets in asthma, as well as in a variety of other oxidant-
stress related murine models of lung injury in these mice. In addition, glutathione signaling 
was shown to be differentially utilized as an effector to regulate gene expression in Nrf2 
dependent and independent pathways 28. These studies added further support to the central 
biologic role of the glutathione tripeptide in cellular redox homeostasis 28, 29.  
These studies in the Nrf2 null mouse models of increased susceptibility to oxidant stress 
suggested that oxidant stress is causal in various forms of lung injury, including asthma. 
They supported epidemiologic studies that linked antioxidant intake with decreased risk of 
asthma severity 30, 31, and reinvigorated a search for antioxidant therapeutics to treat asthma 
despite the fact that single antioxidant agents were largely ineffective in clinical trials. In 
adition, studies using a mouse model of impaired glutathione metabolism together with 
those using glutathione precursors to manipulate glutathione homeostasis raised the 
possibility that antioxidants from separate intracellular or extracellular pools may be 
relevant for different cell types during asthma pathogenesis, such as immune cells during 
sensitization and epithelial cells in response to inflammation 12, 14.  
Taken altogether, these studies suggest different strategies that could be explored to develop 
novel antioxidant therapeutics for asthma. The first is a broad-based approach using 
activators of the Nrf2 pathway to induce an array of antioxidant genes to widely augment 
cellular antioxidant defense 15. One caveat, however, is that the therapeutic benefits of this 
broad-based approach cannot exclusively be attributed to an "antioxidant" mechanism of 
action. Nrf2 controls many cytoprotective genes in addition to known antioxidants, and 
these genes are also expressed at much lower levels in Nrf2 null versus normal mice 11, 28, 32. 
In addition, the more severe asthmatic phenotype in Nrf2 null mice is associated not only 
with increased oxidative stress, but also with increased inflammation. Since loss of Nrf2 
does not appear to control production of Th2 cytokines directly, the increased inflammation 
is attributable to an oxidative stress-mediated activation of pro-inflammatory transcription 
factors, such as NF-κB 33. Nonetheless, such observations make it difficult to dissociate 
antioxidant from anti-inflammatory effects, or from effects on cytoprotective pathways other 
than those involving antioxidant enzymes, in strategies involving Nrf2 modulation.  
A second and more specific therapeutic approach could be designed around more localized, 
or ROS-specific, interventions using synthetic antioxidant compounds, or agents that 
otherwise modulate levels of downstream effects of oxidants. Examples of this include 
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glutathione selective approaches to augment content in extracellular pools by targeting 
glutathione metabolism in lung lining fluid 14, 34 or intracellular pools using glutathione 
precursors 12. Other approaches that have been suggested include mitochondria-targeted 
antioxidants 6 or synthetic catalytic ROS scavengers 35, 36 that can gain intracellular access, in 
some cases mitochondrial access 37, 38. 
2. Therapeutic approaches 
Broad-based strategy based on Nrf2 pathway activation. Characterization and design of 
compounds that can activate the Nrf2 pathway are an active focus of research for 
inflammatory disease and cancer chemoprevention 39-41 (also www.reatapharma.com). A 
group of synthetic triterpenoids are now known to exhibit cytoprotective, antioxidant and 
anti-inflammatory activity largely thru activation of the Nrf2 pathway and are under intense 
characterization and development as potent Nrf2 activators 42. CDDO-Im is a well 
characterized compound that can be delivered enterally and has shown therapeutic benefits 
in mouse models of hyperoxic acute lung injury 43, cystic fibrosis-like lung disease 44 and 
lung cancer 45. There are no reports, as of yet, on the usage of an Nrf2 activator in allergic 
asthma. But the synthetic triterpenoid CDDO-Im has been shown to induce Nrf2-mediated 
activity and protection through its action in normal mice exposed to cigarette smoke as a 
model of chronic obstructive pulmonary disease, COPD, as compared to Nrf2 null mice. 
These results are instructive with regard to oxidant stress and airway function 46. The 
oxidant burden in COPD results not only from infiltration of the lung with inflammatory 
cells (which are mainly neutrophils in contrast to eosinophils in allergic asthma), but also 
from cigarette smoke itself and markers of oxidant stress have been consistently 
demonstrated in the lung and the blood of smoke-exposed mammals 47, 48. Certain COPD 
phenotypes include lung cell injury and death, enlargement of alveoli and eventually right 
heart failure. All of these changes were modeled in normal mice exposed to cigarette smoke 
and all were attenuated by concomitant delivery of CDDO-Im as measured by decreased 
levels of oxidant stress, cellular apoptosis, alveolar destruction and pulmonary 
hypertension. Furthermore, when Nrf2 null mice were exposed to cigarette smoke, these 
changes were all magnified, compared to normal mice, and protection by CDDO-Im was 
absent, supporting the notion that this compound requires Nrf2 for much of its activity 46.  
Interestingly, oxidant stress was assessed by total glutathione content of the lung which 
decreased acutely with exposure to cigarette smoke and increased over time in normal mice 
but not in Nrf2 null mice. Treatment with CDDO-Im increased lung glutathione even in 
normal mice exposed to air as a control, given that this compound is an electrophile itself, 
but again not in Nrf2 null mice. The genes for glutathione synthesis, γ-glutamyl cysteine 
ligase and glutathione synthetase, are known Nrf2 targets. The former is the rate limiting 
enzyme for glutathione synthesis, and its activity is regulated by glutathione levels thru 
feedback inhibition 49. Hence increasing content of this synthetic enzyme is permissive to an 
increase in glutathione content to reset feedback inhibition anew. This stimulation has the 
potential to be developed for increased protection of an “at risk” population exposed to 
primary or second-hand smoke 46. Even though single candidate association studies have 
not implicated these glutathione synthetic genes in asthma or COPD, they have implicated 
the glutathione-S-tranferase genes GSTM1 and GSTP1, suggesting a role for glutathione 
derivatives with airway inflammation 50. Lastly, treatment with CDDO-Im did increase lung 
glutathione weakly in Nrf2 null mice exposed to cigarette smoke. This suggests an Nrf2-
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independent mediator for some CDDO-Im activity that may be fulfilled by an Nrf2-related 
gene, such as Nrf1 51 or an Nrf2-independent pathway 39, 40.  
Regarding lung inflammation in this mouse model of COPD, the inflammatory load, assessed 
thru broncho-alveolar lavage, was similar in cigarette smoke-exposed normal mice regardless 
of treatment with CDDO-Im 46. Hence induction of Nrf2-regulated genes was sufficient to 
protect against cell injury and death in the cigarette smoke exposed lung despite a similar 
degree of inflammation. The array of antioxidant and detoxifying genes may have provided a 
much broader level of protection than that afforded by any single antioxidant therapy. The 
findings in COPD models suggest that CDDO-Im and similar agents should also be 
investigated as potential asthma treatments. Since inflammation is a prominent feature of 
established asthma, even in remission, it is possible that this treatment may have to be 
continued on a chronic basis to prevent future exacerbations. In this regard, CDDO-Im can 
attenuate cytokine and chemokine expression in LPS-stimulated neutrophils 52 and thereby 
decrease the inflammatory response. If CDDO-Im can produce similar results in models of 
allergic inflammation, it could be used to prevent severe exacerbations of asthma. Such as 
approach is warranted as it has recently been reported that Nrf2 protein itself is susceptible to 
suppression and inactivation in children with severe asthma when oxidant stress is intense 53. In 
adult atopic asthmatics, allergen-provoked airway inflammation also suppresses Nrf2 protein 
function and this can be attenuated by larger than usual dosing of Vitamin E 54. The ultimate 
ability of Vitamin E to rescue Nrf2 function under intense oxidant stress is not yet known. 
Selective strategies based on ROS-scavenging or other antioxidant-modulating 
compounds. These strategies would, in contrast to the very broad Nrf2-modulating 
approach described above, administer compounds with their own antioxidant properties, or 
others that specifically modulate endogenous antioxidants. As an example of the latter 
approach, genetic or pharmacological modulation of endogenous pools of glutathione 
(GSH) has beneficial effects in asthma models 12,13,14.  
Glutathione Modulating Reagents: The central role of glutathione in antioxidant defense 
and signal transduction, was described previously in the literature 55-57 and largely 
reinforced by studies with Nrf2 28, 29. Studies with the Nrf2 null mice demonstrated that loss 
of the Nrf2 pathway perturbed lung glutathione homeostasis in the ovalbumin model of 
asthma 11. And recent literature demonstrated that glutathione alone can serve a direct role 
in asthma. In one example from the author’s laboratory, genetic loss of glutathione 
metabolism in lung lining fluid was shown to augment the concentration of the extracellular 
glutathione pool and prevent EGF receptor activation, airway epithelial cell mucin gene 
induction and airway hyperreactivity in a cytokine-driven model of asthma (Figure 1) 14. 
Loss of glutathione metabolism resulted from the genetic absence of the regulatory enzyme  
γ-glutamyltranferase (GGT) 58, 59. Furthermore, asthma could be limited in normal mice by 
inhibiting their lung lining fluid GGT pharmacologically with the compound acivicin.  
A second example of pharmacologically modulating GSH pools involved the glutathione 
precursor γ-glutamylcysteinylethyl ester (γ-GCE) which was shown to effectively augment 
reduced cellular glutathione content (GSH) and redox ratio (GSH/GSSG) in antigen 
presenting cells to limit pro-inflammatory gene induction and attenuate lung inflammation 
in the ovalbumin model of asthma 12. Previous studies with cysteine precursors produced 
similar results but difference in cell permeability were hypothesized to limit overall 
effectiveness 13, 60, 61. A potential advantage of these two strategies is that their therapeutic 
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targets are more selective and focused on glutathione homeostasis itself as compared to the 
broad array of antioxidant and other cytoprotective genes activated by Nrf2. 
Our finding that loss of glutathione metabolism in lung lining fluid could actually attenuate 
asthma was rather unexpected. Lung lining fluid (LLF) is a continuous but very thin layer of 
fluid that bathes the epithelial surface of the lung 62 and shields alveolar cells against 
environmental and endogenous toxins, including oxidants. LLF contains an abundance of 
antioxidants, including reduced glutathione 63. This extracellular pool of glutathione buffers 
hypohalous acid, a potent oxidant from inflammatory cells 64 and inhaled chlorine gas 65, 
limits hydrogen peroxides and lipid peroxide accumulation in conjunction with 
extracellular glutathione peroxidase 66, and maintains bioavailability of other small 
antioxidant molecules, such as nitric oxide 67, ascorbic acid 68, and alpha-tocopherol 69. In 
humans with asthma, the abundance of LLF glutathione content is increased beyond the 
normal level and the magnitude of this increase is inversely related to asthma severity 70. 
Metabolism of LLF glutathione is regulated by a single extracellular enzyme, GGT, that is 
associated with surfactant phospholipid 71. Glutathione metabolism supplies cells with 
cysteine, the rate-limiting amino acid for glutathione biosynthesis. In the presence of oxidant 
stress, cells in the lung induce GGT 72 via Nrf2 signaling 73, 74 to maintain cysteine 
availability for enhanced glutathione synthesis. In the absence of GGT, cells becomes 
starved for cysteine and glutathione deficiency results 58, 75. Indeed in the GGTenu1 mouse 
model of GGT deficiency, lung cells are glutathione deficient and under oxidant stress even 
in normoxia, and this is magnified in hyperoxia 76. The presence of oxidant stress at baseline 
suggested that the GGTenu1 mouse would be more susceptible to asthma, which could then 
be attenuated by restoring cellular glutathione with a cysteine precursor 75, 77, 78. However, in 
a cytokine-driven model of allergic inflammation, cellular glutathione deficiency did not 
predispose the GGTenu1 mouse to asthma. Rather, in the absence of metabolism, LLF 
glutathione content in the GGTenu1 mouse increased well beyond its mildly elevated baseline 
level, buffered oxidant stress and shielded the GGTenu1 mouse lung against asthma, even 
though the level of inflammation matched that of the asthma-susceptible normal mouse 
lung 14. Moreover, asthma susceptibility in the normal mouse lung could be attenuated by 
inhibiting normal LLF GGT activity with the irreversible GGT inhibitor acivicin. To do this 
effectively, however, acivicin had to be delivered thru the airway (inhaled), as opposed to 
the systemic circulation 14.  
These studies provided several insights about asthma and oxidant stress. First, the 
extracellular LLF glutathione pool can shield lung epithelial cells against oxidant-mediated 
induction of mucin gene expression and preserve barrier function despite cellular 
glutathione deficiency. Second, not all cellular sites of oxidant stress are directly casual in 
asthma. Endothelial, bronchial epithelial and alveolar macrophages of GGTenu1 lung exhibit 
oxidant stress at baseline, but methacholine-induced airway hyperreactivity is absent. Third, 
the LLF glutathione pool serves a dual role in antioxidant defense and cysteine supply with 
glutathione metabolism regulating the balance. As the key regulator of this metabolism, 
GGT is a novel target to treat asthma as it is accessible to inhibition thru the airway via its 
presence in lung surfactant and its modulation can augment the antioxidant capacity within 
LLF. Although acivicin can irreversibly inhibit GGT, there is a critical problem associated 
with its usage from a pharmaceutical point of view and that is CNS toxicity in vivo and 
inhibition of several glutamine-dependent biosynthetic enzymes. The recent design and 
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synthesis of a series of γ-phosphono diester analogues of glutamate as GGT inhibitors 
helped overcome this concern 79. The lead compound in this class of compounds is currently 
the most promising candidate for pharmaceuticals to chemically inactivate GGT activity  
in vivo. This compound does inhibit lung GGT activity and its advantages include greater 
specificity, potency, and lack of toxicity 34. Lastly, cellular glutathione deficiency can be 
averted by providing a cysteine precursor or the glutathione precursor γ-
glutamylcysteinylester (γ-GCE). Esterification of glutathione as a means to increase its 
membrane permeability was described by Alton Meister 80. γ-glutamylcysteinyl ester uptake 
appears to be even more efficient than glutathione and it is directly converted to glutathione 
by glutathione synthetase which bypasses the rate-limiting enzyme γ-GCS. Hence it is 
feasible to augment both cellular and extracellular glutathione content using a combination 
of these reagents. 
Synthetic catalytic antioxidant mimetic compounds: Superoxide dismutases (SOD) are key 
endogenous antioxidant defense enzymes, converting superoxide to hydrogen peroxide. 
There are three forms of SOD, cytosolic (SOD1), extracellular (ECSOD or SOD3) and 
mitochondrial (SOD2) and various studies have implicated one or more of the SOD enzymes 
in lung disease 81. Compared to other tissues, the lung has very high levels of ECSOD, 
localized in the vasculature and airways. Its localization, as well as its upregulation during 
inflammation and the increased SOD activity detected in BAL from asthma patients, makes 
it attractive to speculate that ECSOD plays a role in asthma. However, the relatively mild 
phenotype shown by mice lacking ECSOD in asthma models leaves the involvement of 
ECSOD unclear 82. The mitochondrial form of SOD (MnSOD or SOD2) is oxidatively 
inactivated in asthmatic airway samples 4, suggesting that impairment of mitochondrial 
oxidative defenses might contribute to the asthmatic phenotype. Evidence for mitochondrial 
injury in murine asthma models 2, 3, discussed earlier, is consistent with this hypothesis, 
though the mechanism(s) of mitochondrial damage have not been elucidated. SOD2 
polymorphisms are also associated with bronchial hyperresponsivenss in humans 83. The 
product of SOD, hydrogen peroxide, is neutralized by several different enzymes, including 
not only catalase but also various peroxidases including glutathione peroxidase, using 
glutathione as a substrate 81, 84. Along with SOD, hydrogen peroxide scavenging enzymes 
have also been detected in the lung lining fluid 85, and may also contribute to defense 
against asthmatic responses. Such findings, overall, do imply that supplementation of the 
right antioxidant enzyme(s) at the right location(s) could be a viable therapeutic approach 
for asthma. To avoid the many pharmaceutical challenges, including stability, intracellular 
accessibility, and expense, associated with therapeutic use of proteins, some investigators 
have developed low molecular weight synthetic compounds with antioxidant activities. In 
particular three classes of Mn complex have been studied as catalytic antioxidant enzyme 
mimetics with efficacy in various disease models, including those involving the lung 81, 85. 
Porphyrin Mn complexes 36 and salen Mn complexes 35 are multifunctional catalytic 
antioxidant compounds, acting on superoxide, hydrogen peroxide, and certain reactive 
nitrogen species. Macrocyclic Mn complexes, such as M40403, are a class of compounds 
reported to have SOD activity, with no hydrogen peroxide scavenging properties 86. Chang 
and Crapo 87 reported that the Mn porphyrin AEOL-10150 suppressed inflammation and 
improved airway physiology in a murine allergic asthma model. M40403, a lead macrocyclic 
complex, was shown to be similarly effective in a guinea pig ovalbumin-induced asthma 
model 88. While there have not yet been reports of their effects in asthma models, salen Mn 
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complexes, exemplified by compounds such as EUK-189 and a newer cyclized analog EUK-
207, are also of potential interest. These compounds have efficacy in other lung injury 
models, such as a porcine ARDS 89 and pulmonary radiation injury 90, 91 models. As 
compared to several other agents tested, salen Mn complexes were effective at preventing 
severe oxidative pathologies in mice lacking SOD2, implying that these compounds have the 
ability to protect the mitochondria 38. Certain Mn porphryin compounds have also shown 
efficacy in mitochondrial injury models 37, 92, while M40403 did not rescue mice lacking 
SOD2 93. If, indeed, mitochondrial injury is important in asthma, then the effects of such 
multifunctional ROS/RNS scavenging compounds deserve further study as potential 
asthma therapeutics. Unlike these Mn complexes, which have broader effects, certain other 
antioxidant compounds were designed to specifically target the mitochondria 6, 94, 95. While 
there has been no report yet testing such agents in asthma models, it seems likely that, 
because of the multiple potential sites of oxidative injury in asthma, an approach targeted 
only at the mitochondrial would not be optimally effective. It is worth noting, as well, that 
both Mn complexes that improved airway physiology in asthma models also suppressed 
inflammation. As was the case for the Nrf2 null mouse, this makes it difficult to sort out 
whether their therapeutic benefit is due primarily to their anti-oxidant properties, or is 
secondary to their anti-inflammatory effects. This is in contrast to the approaches aimed 
specifically at lung lining fluid GSH, where airway physiology and oxidative stress were 
improved in the absence of any suppression of inflammation. Certainly, a better 
understanding of the mechanism(s) and site(s) of action of a given agent will help to 
facilitate its successful use as an asthma drug. And potentially, for a disease as complex as 
asthma, combination therapies consisting of both anti-inflammatory and selected 
antioxidant compounds would be more effective than any agent given alone.  
3. Summary 
Oxidant stress induced by the accumulation of oxidants in excess of antioxidant defense 
plays a causal role in asthma. Recent studies in mouse models of asthma have drawn 
attention to the roles of oxidant stress and antioxidant defense in cellular and extracellular 
sites of the lung. Cellular sites of oxidant stress during immune cell activation and 
extracellular sites of oxidant stress in lung lining fluid may play distinct roles during the 
early phase of sensitization to allergens and the late phase of lung response to inflammation, 
respectively. It also appears that not all sites of oxidant stress are necessarily directly related 
to the development of AHR. Novel strategies to treat asthma may involve activation of the 
Nrf2 pathway and its array of antioxidant and cytoprotective genes, although the necessity 
of all of the genes is not yet clear, nor are the long term effects of deactivation of this 
pathway on normal cell function and asthma progression. Alternative strategies designed to 
modulate lung cell or lung lining fluid glutathione or to administer synthetic antioxidants 
with more specific ROS targets or other properties may (as compared to the broad panel of 
Nrf2-regulated antioxidants) provide a more focused approach to control pro-inflammatory 
stimuli and lung antioxidant defense. Of further interest would be whether the strategy, 
while acting against oxidative stress, is also anti-inflammatory (e.g. Nrf2 activation) or 
whether it appears to act downstream of inflammation (e.g. GGT inhibition to increase 
extracellular GSH). Communication of epithelial cell injury to the adaptive immune system 
and activation of airway inflammation are common themes identified in human genome-
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wide association studies (GWAS) to date, although genes with known antioxidant functions 
are not readily apparent in susceptibility loci 96. GWAS studies have also confirmed the 
genetic heterogeneity of asthma 96-98. The causal mechanisms underlying any of these gene 
associations, however, are yet to be defined. Overall these data suggest that combinations of 
multiple agents are likely to be more effective than any agent alone. These might be agents 
that combat oxidative stress, through the various mechanisms discussed here, in 
combination with other treatments acting by distinct mechanisms to modulate anti-cytokine 
or anti-inflammatory pathways.  
Abbreviations: SOD, superoxide dismutase; Nrf2, NF-E2 related factor 2; ARE, antioxidant 
response element; GSH, glutathione; GSSG, glutathione disulfide; GGT, gamma-glutamyl 
transferase; ROS, reactive oxygen species; LLF, lung lining fluid; BAL, bronch-alveolar 
lavage; CDDO-Im, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; GWAS, 
genome-wide association study.  
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